Estrogen News and Research

Latest Estrogen News and Research

Research programs embody the promise of anti-aging medicine.

Sometimes the value of research lies as much in exposing false remedies as in discovering true breakthroughs. Scientists at the country's first school of gerontology and in laboratories around the University of Southern California do both, mindful of their responsibility to a society focused on healthful aging.

13 Dec 2010

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Genetic changes in HDAC9 gene may modulate onset of ER positive breast cancer and its recurrence

Investigators at The Cancer Institute of New Jersey have presented new research at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium. Their work highlights how a variation in a person's DNA sequence is associated with an earlier age of onset for breast cancer that is stimulated by the hormone estrogen (estrogen receptor positive).

13 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

OpEds: Palin on the Ryan Roadmap, Seniors and primary care docs, Arizona transplant controversy

[The president's National Commission on Fiscal Responsibility and Reform's report] implicitly endorses the use of 'death panel'-like rationing by way of the new Independent Payments Advisory Board—making bureaucrats, not medical professionals, the ultimate arbiters of what types of treatment will (and especially will not) be reimbursed under Medicare.

10 Dec 2010

HRT with estrogen alone may reduce risk of breast cancer: Study

While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk, according to study results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

10 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients - those with estrogen receptor (ER)-positive/HER2-negative disease.

10 Dec 2010

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.

10 Dec 2010

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

10 Dec 2010

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.

9 Dec 2010

Oral contraceptives account for less than 1% of estrogen in drinking water

Contrary to popular belief, birth control pills account for less than 1 percent of the estrogens found in the nation's drinking water supplies, scientists have concluded in an analysis of studies published on the topic.

9 Dec 2010

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Bionovo, today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that stimulate the production of or activate ERb are potential new therapies to prevent breast cancer.

9 Dec 2010

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

While the medical community continues to debate the benefits of CYP2D6 genetic testing for women on the breast cancer treatment tamoxifen, patients using the medication are anxious to have the tests. According to a new survey of more than 700 women with breast cancer currently taking tamoxifen, almost 80 percent of respondents would choose to have a genetic test that determines CYP2D6 genotype, yet only 14 percent of these women have been tested. CYP2D6 is an enzyme that influences how well the body processes tamoxifen into its more active form.

7 Dec 2010

NanoString secures exclusive worldwide license to develop products for breast cancer intrinsic subtyping

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced it has secured an exclusive worldwide license from Bioclassifier, LLC to develop in vitro diagnostic and research products for breast cancer intrinsic subtyping.

From NanoString Technologies 7 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Seven studies on Oncotype DX breast cancer test to be presented at 33rd CTRC-AACR SABCS

Genomic Health, Inc. today announced that the company will present results from seven studies at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010 at the Henry B. Gonzalez Convention Center.

4 Dec 2010

New standard treatment for early stage breast cancer

Spanish Oncology has established a new standard treatment for Breast Cancer at early stages thanks to the results of the study 9805/Target 0 funded by Spanish Breast Cancer Research Group and sponsored by Sanofi Aventis.

4 Dec 2010

Experts reach consensus on beneficial effects of Soy

According to the December 2010 Journal of Nutrition Supplement titled, "Soy Summit: Exploration of the Nutrition and Health Effects of Whole Soy," consensus has been reached among leading soy science experts surrounding three main areas of debate: soy and women's health, soy and heart health, and soy and overall nutrient adequacy. Leading soy experts agree that including soyfoods in a balanced diet will have beneficial effects and improve nutrient intake among the U.S. population.

3 Dec 2010

Estrogen News and Research

Latest Estrogen News and Research

Research programs embody the promise of anti-aging medicine.

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Genetic changes in HDAC9 gene may modulate onset of ER positive breast cancer and its recurrence

Depression drug appears effective in reducing pain associated with breast cancer treatment

OpEds: Palin on the Ryan Roadmap, Seniors and primary care docs, Arizona transplant controversy

HRT with estrogen alone may reduce risk of breast cancer: Study

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Oral contraceptives account for less than 1% of estrogen in drinking water

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

NanoString secures exclusive worldwide license to develop products for breast cancer intrinsic subtyping

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Seven studies on Oncotype DX breast cancer test to be presented at 33rd CTRC-AACR SABCS

New standard treatment for early stage breast cancer

Experts reach consensus on beneficial effects of Soy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Estrogen News and Research

Latest Estrogen News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in